Biotech News
Related news
COCPCocrystal Pharma2026-04-02 12:00 EST
Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive
ENTAEnanta Pharmaceuticals2026-06-23 09:10 EST
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
OGENOragenics2026-03-10 12:30 EST
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
VIRIVirios Therapeutics2026-04-15 13:00 EST
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
ABUSArbutus2026-07-16 11:30 EST
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
PHARPharming Group2026-03-24 06:00 EST
Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
SPROSpero Therapeutics2026-06-17 17:36 EST
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
ABUSArbutus2026-05-13 11:30 EST
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
PHARPharming Group2026-06-04 05:00 EST
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
AVIRAtea2026-07-14 11:00 EST
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
Arbutus
Hepatitis B Therapeutics Arbutus Biopharma develops therapies intended to achieve a functional cure for chronic hepatitis B. Its current clinical strategy centers on suppressing viral antigen production with RNA interference. Imdusiran Imdusiran is an RNA interference therapeutic that reduces production of hepatitis B viral proteins,...
Recent company news
ABUSArbutus2026-08-12 11:30 EST
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
ABUSArbutus2026-07-16 11:30 EST
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
ABUSArbutus2026-05-13 11:30 EST
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
ABUSArbutus2026-04-15 11:30 EST
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
ABUSArbutus2026-03-23 11:30 EST
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Stock data
- Close
- 4.71 USD
- Market cap
- 841.51M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States